Skip to main content
ORAGENICS INC logo

ORAGENICS INC — Investor Relations & Filings

Ticker · OGEN ISIN · US6840233026 LEI · 549300639MGD19K4ZW90 US Professional, scientific and technical activities
Open in API
Filings indexed 1,006 across all filing types
Latest filing 2026-05-20 Proxy Solicitation & In…
Country US United States of America
Listing US OGEN

About ORAGENICS INC

https://www.oragenics.com/

Oragenics, Inc. is a development-stage biotechnology company focused on developing therapeutics for neurological disorders. The company utilizes a proprietary intranasal delivery technology for targeted, non-invasive administration of pharmaceutical medications to the brain. Its lead candidate, ONP-002, is being developed as a potential treatment for concussion. The company's platform technology is also being explored for applications in other neurodegenerative diseases and central nervous system (CNS) disorders, with the goal of transforming patient care in neurology.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement
2026-05-20 English
DEF 14A
Proxy Solicitation & Information Statement
2026-05-20 English
8-K
Regulatory Filings Classification · 85% confidence The text is a Form 8-K “Current Report” filed with the SEC under the Exchange Act. It includes Item 7.01 Regulation FD Disclosure and attaches an investor presentation (Exhibit 99.1) and press releases (Exhibits 99.2, 99.3). It is not an earnings release, annual report, or financial statement; it is a regulatory compliance filing. Therefore it falls into the fallback category of Regulatory Filings (RNS).
2026-05-19 English
10-Q - ORAGENICS INC (0001174940) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-08 English
8-K - ORAGENICS INC (0001174940) (Filer)
Regulatory Filings Classification · 97% confidence The document is a U.S. SEC Form 8-K “Current Report” (dated May 7, 2026) disclosing Item 8.01 “Other Information” (a press release attached as Exhibit 99.1 regarding a Letter of Intent). There are no substantive financial statements or specialized topics (e.g., earnings release, M&A, dividends). This is a general regulatory current report, best classified under the fallback “Regulatory Filings (RNS).”
2026-05-07 English
8-K - ORAGENICS INC (0001174940) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports a specific event dated April 13, 2026, namely the dosing of the first patient in a Phase IIa clinical trial by Oragenics, Inc. The document includes a press release as an exhibit and signatures from the CEO. The length is 3897 characters, which is relatively short and typical for an 8-K filing. The content is an event update rather than a full financial report or earnings release. Form 8-K filings are generally classified under Regulatory Filings (RNS) as they cover miscellaneous current event disclosures that do not fit other specific categories.
2026-04-13 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.